SpyGlass completes enrollment in trial of long-term drug delivery platform for glaucoma
Click Here to Manage Email Alerts
SpyGlass Pharma has completed enrollment in its phase 1/2 clinical trial evaluating a long-term drug delivery platform of bimatoprost for glaucoma and ocular hypertension, according to a press release.
“As we know from multiple studies, patients struggle being adherent to chronic use of topical medications,” Patrick Mooney, the company’s CEO, told Healio. “SpyGlass is working hard to improve care for glaucoma patients and eye care professionals, and we believe our drug delivery platform is a significant advance over current options today.”
According to the release, the platform is implanted during routine cataract surgery and designed to release 3 years of bimatoprost to targeted tissues.
“Today’s drug delivery options offer limited durability measured in months,” Mooney said. “Our lead product with bimatoprost is targeting 3 years of IOP-lowering for patients with glaucoma or ocular hypertension, and we see this as a significant advance forward.”
The multicenter, randomized controlled trial will assess IOP reduction among adults with mild to moderate open-angle glaucoma or hypertension, comparing the SpyGlass platform with timolol maleate ophthalmic solution 0.5% over 36 months.
“We look forward to sharing these results in time to build upon the compelling clinical data from our first-in-human trial, demonstrating significant IOP-lowering and excellent vision 18 months after implantation,” Mooney told Healio.
Reference:
- Evaluation of the bimatoprost implant system used in combination with the SpyGlass intraocular lens compared to timolol ophthalmic solution (Tigris). https://clinicaltrials.gov/study/NCT06120842. Published Oct. 15, 2024. Accessed Nov. 26, 2024.
Collapse
Read more about
Click Here to Manage Email Alerts